Experienced in Thrombocytopenia

Dr. Anasuya Gunturi

Hematology | Oncology
Lgh Medical Group, Inc.
295 Varnum Ave, 
Lowell, MA 
Accepting New Patients
Offers Telehealth
16 Years of Experience
Experienced in Thrombocytopenia
Lgh Medical Group, Inc.
295 Varnum Ave, 
Lowell, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anasuya Gunturi is a Hematologist and an Oncologist in Lowell, Massachusetts. Dr. Gunturi has been practicing medicine for over 16 years and is rated as an Experienced provider by MediFind in the treatment of Thrombocytopenia. Her top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Breast Cancer, and Angiosarcoma. Dr. Gunturi is currently accepting new patients.

Her clinical research consists of co-authoring 5 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Hematology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Lowell General Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

LGH MEDICAL GROUP, INC.
295 Varnum Ave, Lowell, MA 01854

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
View 4 Less Clinical Trials

5 Total Publications

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.
Journal: Journal for immunotherapy of cancer
Published: April 11, 2016
Similar Doctors
Elite in Thrombocytopenia
Dr. David J. Kuter
Hematology | Oncology
Elite in Thrombocytopenia
Dr. David J. Kuter
Hematology | Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (24.1 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Kuter is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Kuter is rated as an Elite provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Thrombocytopenia, Autoimmune Hemolytic Anemia, and Splenectomy. Dr. Kuter is currently accepting new patients.

Distinguished in Thrombocytopenia
Dr. Nathan T. Connell
Hematology | Hematology Oncology
Distinguished in Thrombocytopenia
Dr. Nathan T. Connell
Hematology | Hematology Oncology

Brigham And Womens Physicians Organization Inc

75 Francis St, 
Boston, MA 
 (24.6 miles away)
617-732-5500
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nathan Connell is a Hematologist and a Hematologist Oncology provider in Boston, Massachusetts. Dr. Connell is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Von Willebrand Disease (VWD), Thrombocytopenia, Sickle Cell Disease, and Blood Clots. Dr. Connell is currently accepting new patients.

Distinguished in Thrombocytopenia
Dr. Katayoon Goodarzi
Hematology | Oncology
Distinguished in Thrombocytopenia
Dr. Katayoon Goodarzi
Hematology | Oncology

The General Hospital Corporation

2014 Washington St, 
Newton, MA 
 (22.4 miles away)
617-219-1200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Katayoon Goodarzi is a Hematologist and an Oncologist in Newton, Massachusetts. Dr. Goodarzi is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. Her top areas of expertise are Thrombocytopenia, Shwartzman Phenomenon, Adult Immune Thrombocytopenia, and Immune Thrombocytopenic Purpura (ITP). Dr. Goodarzi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gunturi's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 27 Advanced Conditions
    View All 100 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile